MindMed to Host Earnings Call to Discuss Second Quarter 2022 Financial Results and Provide Business Update
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced it will host an earnings call on August 11, 2022, at 4:30 p.m. EDT to discuss its financial results for the quarter ended June 30, 2022, alongside a business update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced it will host an earnings call on August 11, 2022, at 4:30 p.m. EDT to discuss its financial results for the quarter ended June 30, 2022, alongside a business update. The company focuses on developing innovative products targeting brain health disorders, including psychiatry and addiction. Stakeholders can join the call via telephone or watch the webcast, which will also be archived for 30 days.
Details
News Market Reaction – MNMD
The recorded move for MNMD in the trading session of this news was -0.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Thursday, August 11, 2022, at 4:30 p.m. EDT to discuss its financial results for the quarter ended June 30, 2022 and provide a business update.
Individuals may participate via telephone by dialing (800) 920-2776 (domestic) or (416) 981-9033 (international) and using conference ID 22019820. The webcast can be accessed live here or on MindMed's Investor Resources webpage. The webcast will be archived on the company's website for at least 30 days after the conference call.
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-host-earnings-call-to-discuss-second-quarter-2022-financial-results-and-provide-business-update-301599817.html
SOURCE Mind Medicine (MindMed) Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.